Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences, Inc. (RNA) Cash from Operations (2019 - 2025)

Avidity Biosciences' Cash from Operations history spans 7 years, with the latest figure at 169773000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 69.99% year-over-year to 169773000.0; the TTM value through Dec 2025 reached 650441000.0, down 116.19%, while the annual FY2025 figure was 650441000.0, 116.19% down from the prior year.
  • Cash from Operations reached 169773000.0 in Q4 2025 per RNA's latest filing, down from 156173000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 16501000.0 in Q4 2023 to a low of 199666000.0 in Q2 2025.
  • Average Cash from Operations over 5 years is 65072800.0, with a median of 44078000.0 recorded in 2022.
  • Peak YoY movement for Cash from Operations: skyrocketed 142.11% in 2023, then tumbled 705.24% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 26215000.0 in 2021, then crashed by 49.49% to 39189000.0 in 2022, then surged by 142.11% to 16501000.0 in 2023, then crashed by 705.24% to 99871000.0 in 2024, then crashed by 69.99% to 169773000.0 in 2025.
  • Per Business Quant, the three most recent readings for RNA's Cash from Operations are 169773000.0 (Q4 2025), 156173000.0 (Q3 2025), and 199666000.0 (Q2 2025).